These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

Objective Our objective was to evaluate the effects of long-term reduced training on the left atrium (LA) in elite endurance ...